RecruitingPhase 4NCT07030517

A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

Studying Hinman syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Johnson & Johnson Private Limited
Principal Investigator
Johnson & Johnson Private Limited Clinical Trial
Johnson & Johnson Private Limited
Intervention
Teclistamab(drug)
Enrollment
75 target
Eligibility
18 years · All sexes
Timeline
20252027

Study locations (12)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07030517 on ClinicalTrials.gov

Other trials for Hinman syndrome

Additional recruiting or active studies for the same condition.

See all trials for Hinman syndrome

← Back to all trials